Psyence BioMed launches US ibogaine subsidiary

Psyence BioMed's new US subsidiary

Psyence BioMed Ltd., a biopharmaceutical company listed on Nasdaq, has announced the formation of a new subsidiary, Texas Ibogaine Research Corporation (TIRC), to advance ibogaine research and development in the United States. The announcement, made on September 14, 2026, highlights the company's strategic move to consolidate its ibogaine efforts within a dedicated US entity.

Focus on regulated ibogaine development

According to the company's press release, TIRC will serve as the central hub for Psyence BioMed's US-based ibogaine activities. This includes managing pharmaceutical-grade supply, regulatory engagements, and potential clinical development. The subsidiary is positioned to hold US rights to ibogaine developed by PsyLabs, contingent on finalizing licensing agreements.

Leadership and operational strategy

Jody Aufrichtig, CEO of Psyence BioMed, will also lead TIRC, with Dr. John Thorne appointed as project lead. The company plans to leverage its internal resources to provide technical, legal, administrative, and financial support for TIRC, ensuring streamlined operations and regulatory compliance.

Why it matters

The establishment of TIRC comes amid increasing interest in regulated ibogaine research in the US. Recent policy developments, including an Executive Order to accelerate neuroplastogen research, underscore the growing momentum. Psyence BioMed's initiative aligns with these efforts, potentially paving the way for new therapeutic options for mental health and substance-use disorders.

Psyence BioMed's move to concentrate its ibogaine development in the US reflects a broader trend of integrating research and regulatory processes within a single entity, aiming to enhance efficiency and compliance with federal and state regulations.